Literature DB >> 9175029

Successful treatment of early secondary myelofibrosis in SLE with IVIG.

A Aharon1, Y Levy, Y Bar-Dayan, A Afek, G Zandman-Goddard, Y Skurnik, F Fabrrizzi, Y Shoenfeld.   

Abstract

Myelofibrosis has been reported as a rare cause of pancytopenia in patients with autoimmune diseases. We describe a 54y old female patient who was admitted with severe anemia subsequently found to be due to marrow fibrosis. During the course of her hospitalization, relying both on her clinical symptoms as well as the results of a wide range of laboratory tests and diagnostic procedures, the diagnosis of systemic lupus erythematosus was established. The patient was treated with high dose steroids, but improvement of her clinical symptoms as well as normalization of her peripheral blood count were achieved only after high dose intravenous therapy with gamma globulin (IVIG) was instituted. Along with the improvement in the peripheral blood parameters normalization of the bone marrow architecture was recorded on a repeated bone marrow biopsy. IVIG therapy should be considered in extreme cases of bone marrow suppression in SLE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175029     DOI: 10.1177/096120339700600412

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Intravenous immunoglobulin and fibrosis.

Authors:  Vered Molina; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Intravenous immunoglobulin therapy and systemic lupus erythematosus.

Authors:  Gisele Zandman-Goddard; Yair Levy; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Current and novel therapeutics in the treatment of systemic lupus erythematosus.

Authors:  Cagri Yildirim-Toruner; Betty Diamond
Journal:  J Allergy Clin Immunol       Date:  2011-02       Impact factor: 10.793

Review 5.  Lessons learned from bone marrow failure in systemic lupus erythematosus: Case reports and review of the literature.

Authors:  Erik Anderson; Bhakti Shah; Anne Davidson; Richard Furie
Journal:  Semin Arthritis Rheum       Date:  2017-12-08       Impact factor: 5.532

Review 6.  Treatment of acute neuropsychiatric lupus with intravenous immunoglobulin (IVIG): a case report and review of the literature.

Authors:  Aaron M Milstone; Kevin Meyers; Josephine Elia
Journal:  Clin Rheumatol       Date:  2005-01-21       Impact factor: 2.980

7.  Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF-β in the bone marrow: a case report.

Authors:  Hiroshi Ohkawara; Miki Furukawa; Kazuhiko Ikeda; Akiko Shichishima-Nakamura; Masahiko Fukatsu; Takahiro Sano; Koki Ueda; Satoshi Kimura; Risa Kanai; Yuka Oka; Fumi Murakami; Osamu Suzuki; Yuko Hashimoto; Kazuei Ogawa; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2017-06-05       Impact factor: 2.490

8.  Experience with monthly, high-dose, intravenous immunoglobulin therapy in patients with different connective tissue diseases.

Authors:  Sevil Kamali; Ayse Cefle; Mehmet Sayarlioglu; Ahmet Gul; Murat Inanc; Lale Ocal; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2004-01-14       Impact factor: 2.631

Review 9.  Pragmatic approaches to therapy for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Nat Rev Rheumatol       Date:  2013-10-29       Impact factor: 20.543

Review 10.  Antifibrosis: to reverse the irreversible.

Authors:  Ziv Paz; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.